In the Margins

Sequoia Fund manager details Valeant experience

March 1, 2016

By Barron's

In its annual report, Sequoia Fund manager Ruane, Cuniff & Goldfarb has vented about Valeant Pharmaceuticals' recent stock plunge, though it offers an optimistic outlook for the stock. The letter outlines how much Valeant’s relationship with affiliated pharmacy Philidor wreaked havoc for the fund company. Read the original story from Barron's.

 

 

Most Read

A Seat at the Table
IDC's Kim aims to expand, improve membership

In his new role heading up Independent Directors Council, Thomas Kim plans to focus on the group's core mission while expanding its presence and influence. "As ...